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Change of treatment modalities over the last 10 years
in pediatric patients with inflammatory bowel disease
in Switzerland
Katharina Guilchera, Nicolas Fournierb, Alain Schoepferc, Susanne Schiblid, Johannes Spalingerd,e,
Christian Braeggerf and Andreas Nydeggera; the Swiss IBD Cohort Study
Background and aim During the past decade, several new drugs were approved for the treatment of pediatric inflammatory
bowel disease (IBD). We aimed to evaluate if and how pharmacologic treatment options for pediatric IBD in Switzerland have
changed over time.
Patients and methods Data from the pediatric Swiss IBD Cohort Study, a national prospective cohort study initiated in 2006,
were analyzed. Patients were divided into two groups: patients with IBD diagnosis until 2009 (168 patients) and patients with IBD
diagnosis in 2010 and after (210 patients). Both groups were analyzed regarding the past and the current therapies as well as
need for surgery.
Results Overall, 378 pediatric patients with IBD were analyzed, of which 51.9% had Crohn’s disease (CD) and 48.1% had
ulcerative colitis/indeterminate colitis. Median age at diagnosis was 12 years. The majority (65.4%) of the patients with ulcerative
colitis experienced pancolitis, whereas 45.4% of patients with CD presented with ileocolonic disease at diagnosis. A decreased
use of corticosteroids in pediatric patients with CD can be found after 2010 (P= 0.041). Use of 5-aminosalicylic acid for patients
with CD was dramatically reduced after the year 2010 (33.5 vs. 67.7% after 6 years of disease). A significant shift toward earlier
use of biologicals could be shown after 2010 (P<0.001). However, there was no significant decrease of surgery rate after 5 years
of disease.
Conclusion In the past decade, a significant earlier use of anti-tumor necrosis factor-α agents in pediatric patients with IBD was
observed with steroid-sparing effect in patients with CD. However, this change was not associated with reduction of surgery. Eur
J Gastroenterol Hepatol 30:1159–1167
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing
gastrointestinal disorder, which comprises Crohn’s disease
(CD) and ulcerative colitis (UC), as well as the nondefined
group of indeterminate colitis (IC). Approximately 25% of
all patients with IBD are diagnosed during childhood or
adolescence [1]. Early aggressive treatment is important to
improve the long-term outcome regarding complications,
especially in children where disease duration exceeds over
many decades. In the past, treatment goals were to achieve
clinical recovery and to improve quality of life. With the
arrival of more potent drugs, like biologicals, these
objectives have changed over the last decade. Nowadays,
besides clinical remission, the achievement of mucosal
healing, prevention of complications such as intestinal
fistulas, abscess formation, and strictures, as well as
growth retardation and delayed puberty are considered to
represent relevant treatment goals. Different treatment
modalities are used including anti-inflammatory drugs (i.e.
mesalazine), corticosteroids, immunomodulators (i.e. aza-
thioprine, methotrexate), and biologicals (i.e. infliximab,
adalimumab). For a long time, corticosteroids have been
used to induce remission in active IBD, but owing to their
well-known adverse effects, especially in decreasing linear
growth, alternative treatment algorithms have been pro-
posed like early use of biologicals or nutritional therapy
with enteral nutrition [2].
The aim of our study was to determine which treatments
were used in pediatric patients with IBD in Switzerland
comparing patients treated up to the year 2009, with
those treated from 2010 onwards and if changes in treat-
ment modalities affected complications.
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Patients and methods
Study design
The following study is a retrospective analysis of prospectively
collected data of pediatric patients enrolled in the Swiss
Pediatric Inflammatory Bowel Disease Cohort Study (SPIBDCS)
with active CD and UC/IC regarding the change of treatment
strategies in Swiss pediatric IBD over time.
Patients
In 2006, the SIBDCS was initiated. It is a national pro-
spective cohort study on patients with IBD in Switzerland
and aims to provide up-to-date information regarding
different aspects of IBD in Switzerland for the Swiss and
international scientific community, public health autho-
rities, and medical staff [3]. For the pediatric subcohort,
the SIBDCS, physician questionnaires as well as patient
questionnaires were adapted for pediatric patients and
their parents.
Up to December 2016, 378 pediatric patients until age
of 16 years in whom diagnosis of CD, UC or IC was made
were included and followed up. As described by Pittet et al.
[3], 74% of patients were recruited at university hospitals,
21% at regional hospitals, and 5% in private outpatient
clinics across Switzerland. The five university centers of
Switzerland were Lausanne, Geneva, Bern, Basel, and
Zurich, as well as the two cantonal hospitals Luzern and
St. Gallen, with the University of Lausanne as coordinating
center and database location. Ethical approval was
obtained for the study protocol by the ethics committee of
Cantons or regions where patients were included, as well
as individual consent of patient and parents. Yearly
patient-reported questionnaires about quality of life, social
impairment, health resources consumption, symptoms,
and yearly physician follow-up questionnaires about
treatments and complications were collected.
Methods
Data from the cohort clinical reporting forms including
demographic variables (age at diagnosis, age at inclusion,
and sex) and medical information as onset of symptoms, date
of diagnosis, initial disease location, initial treatment, current
treatment, past therapies, and extraintestinal manifestations
(EIM) were retrieved by the IBD physician in charge of the
patient or the study nurse in charge of data collection. UC
and IC were summarized for analyses because of the small
number of IC. Disease localization was defined by the
Montreal as well as the Paris classification [4,5]. Both clas-
sifications were applied because patients were included in this
study before the publication of the Paris classification. For
CD, disease location at enrollment was defined as L1: ileal
+ /− limited cecal disease, L2: colonic, L3: ileocolonic, and
L4: isolated upper digestive location. In UC, disease location
was defined as pancolitis for an entirely affected colon, left-
sided colitis for the descending colon, and proctitis for
patients where only the rectum was affected. Patients were
divided into two groups: patients who were diagnosed up to
2009 and patients in whom diagnosis was made in 2010
or later. Both groups were analyzed regarding the past and
the current therapies as well as need for any surgery (i.e.
fistulectomy or fistulotomy, ileal/ileo-cecal and right colon
resection, as well as abscess drainage and proctocolectomy).
Statistical analysis
All statistical analyses were made using the Stata Software
(version 14.2; StataCorp, College Station, Texas, USA)
and the R software (version 3.3.1; R Foundation for
Statistical Computing, Vienna, Austria).
Continuous data distribution was assessed using nor-
mal QQ-plot. Gaussian distributed data were summarized
as mean, SD, and range. Non-Gaussian distributed data
were summarized as median, interquartile range, and
range. Differences in means between two independent
groups for Gaussian distributed data were assessed using
Student’s t-test. For non-Gaussian distributed data, the
nonparametric Mann–Whitney–Wilcoxon rank-sum test
was used.
Categorical data were summarized as raw frequencies
and relative percentages. Differences in distribution of
categorical data between two independent groups were
assessed using the χ2-test or Fisher’s exact test in case of
insufficient sample size.
Times to first treatment initiation or first surgery were
analyzed in a time-to-event manner, including techniques
to deal with left-censored and interval-censored data.
Cumulative proportions of treatment usage according to
time from diagnosis were derived using the Kaplan–Meier
estimator. The log-rank test was used to assess differences
in cumulative proportion curves between several inde-
pendent groups.
For the present study, a P value less than 0.05 was
considered as statistically significant.
Results
Patient’s characteristics
Patient’s characteristics are shown in Table 1. A total of
378 patients were included (54% male; 51.9% had CD,
and 48.1% of patients had UC/IC). Median age at diag-
nosis for both disease groups was 12 (interquartile range:
9–14) years, whereas the median age of enrollment in the
study was 14 years. Approximately two-thirds and almost
50% of patients had severe disease defined by pancolitis
for UC (65.4%) and ileocolonic disease for CD (45.4%) at
diagnosis, respectively. Fistulas and stenosis were observed
in 21.4 and 12.2% of patients with CD, respectively. At
enrollment for patients with CD, the mean z-score for
height was − 0.60 (SD: 1.2) and for weight − 0.51 (SD:
1.1), with a mean BMI z-score at − 0.39 (SD: 1.1). Patients
with UC had a mean z-score for height at − 0.14 (SD: 1.2),
a mean weight z-score of − 0.20 (SD: 1.2), and a mean BMI
z-score of − 0.06 (SD: 1.00) at enrollment. The trend shows
a better height and weight z-score at enrollment for
patients diagnosed at 2010 and later when compared with
patients diagnosed before, which applies to both patients
with CD and those with UC (Table 2).
Extraintestinal manifestations
In our study, 29.4% of children had EIM that were mainly
arthritis (15.9%) and oral ulcers (13.2%). Most of EIM
occurred more often in patients with CD, except primary
sclerosing cholangitis and pyoderma gangrenosum, which
were observed more often in patients with UC (Table 1).
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Treatment modalities
Treatment modalities were studied for the whole study
population, and separately for CD and UC/IC (Table 3).
Two years after diagnosis of CD, 89.5% of all patients
were already treated with immunomodulators and 79.6%
with steroids. Overall, 42% of patients with CD have
received a treatment with biologicals within the first
2 years (Fig. 1a).
In UC, nearly all (93.9%) patients benefitted from a
treatment with 5-aminoacylic acid (5-ASA) within the first
2 years of diagnosis. Moreover, 77.3% needed steroids,
63.2% received an immunomodulatory and only 20.4% a
treatment with biologicals in the same time (Fig. 1b).
Corticosteroids
Corticosteroids are being used for the treatment of acute
disease at diagnosis and flares throughout both time periods.
Almost 90% of patients with CD and UC received corti-
costeroid treatment after 5 years of disease (Fig. 1a and b).
Patients with CD received significantly less corticosteroids
after 2010 (P=0.041). There was, however, no reduction
seen in the use of steroids after 2010 when comparing
patients with UC (P=0.604) or all IBD (P=0.067).
5-Aminoacylic acid
5-ASA is the major therapy for patients with UC and was
used in 93.9% of all patients with UC within the first
Table 1. Demographics of patients
Patients with CD Patients with UC/IC All Patients with IBD P value CD vs. UC
Number of patients 196 (51.9) 182 (48.1) 378 (100.0) –
Sex
Male 114 (58.2) 90 (49.5) 204 (54.0) 0.089
Female 82 (41.8) 92 (50.5) 174 (46.0)
Age at diagnosis (years)
Median (IQR) 12 (10–14) 11 (8–14) 12 (9–14) 0.035
Range 0–16 2–16 0–16
Age at enrollment (years)
Median (IQR) 14 (12–15) 13 (10–15) 14 (11–15) 0.064
Range 1–16 4–16 1–16
Age at latest follow-up (years)
Median (IQR) 16 (15–17) 16 (13–17) 16 (14–17) 0.069
Range 1–18 4–18 1–18
Disease duration (years)
Median (IQR) 3 (2–5) 3 (1–5) 3 (2–5) 0.806
Range 0–15 0–14 0–15
Year of diagnosis
2009 and earlier 92 (46.9) 76 (41.8) 168 (44.4) 0.311
2010 and later 104 (53.1) 106 (58.2) 210 (55.6)
Height z-score at enrollment
Mean (SD) −0.60 (1.2) −0.14 (1.2) −0.38 (1.2) <0.001
Range −4.9 to 2.5 −6.5 to 2.2 −6.5 to 2.5
Weight z-score at enrollment
Mean (SD) −0.51 (1.1) −0.20 (1.2) −0.36 (1.2) 0.009
Range −3.6 to 2.4 −4.5 to 3.0 −4.5 to 3.0
BMI z-score at enrollment
Mean (SD) −0.39 (1.1) −0.06 (1.0) −0.23 (1.1) 0.003
Range −3.7–2.0 −3.1–2.3 −3.7–2.3
Initial disease location (CD)
L1 24 (12.2) – – –
L2 25 (12.7) – – –
L3 134 (45.4) – – –
L4 only 4 (2.0) – – –
Unknown/unclear 9 (4.6) – – –
Initial disease location (UC)
Pancolitis – 119 (65.4) – –
Left-sided colitis – 34 (18.7) – –
Proctitis – 15 (8.2) – –
Unknown/unclear – 14 (7.7) – –
Fistulas
Perianal fistula 30 (15.3) – – –
Other fistula 12 (6.1) – – –
Stenosis
Any stenosis 24 (12.2) – – –
EIM
None 124 (63.3) 143 (78.6) 267 (70.6) 0.001
Yes 72 (36.7) 39 (21.4) 111 (29.4) 0.026
Arthritis 39 (19.9) 21 (11.5) 60 (15.9) 0.451
Uveitis 5 (2.6) 2 (1.1) 7 (1.9) 0.611
Pyoderma gangrenosum 1 (0.5) 2 (1.1) 3 (0.8) 0.038
Erythema nodosum 8 (4.1) 1 (0.6) 9 (2.4) 0.002
Oral ulcers 36 (18.4) 14 (7.7) 50 (13.2) 0.624
Ankylosing spondylitis 3 (1.5) 1 (0.6) 4 (1.1) 0.059
PSC 1 (0.5) 6 (3.3) 7 (1.9) –
CD, Crohn’s disease; EIM, extraintestinal manifestations; IBD, inflammatory bowel disease; IQR, interquartile range; PSC, primary sclerosing cholangitis; UC, ulcerative
colitis.
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2 years of disease. The opposite is the case for patients
with CD, where a significant decrease of the use of 5-ASA
can be observed (P=0.001); in fact, in the period of 2010
and later, only half of the patients were exposed to this
treatment compared with patients treated up to 2009 in
the same time. More precisely, after 6 years of disease, the
use of 5-ASA dropped dramatically from 67.7 to only
33.5% between the two periods (Fig. 2).
Immunomodulators
We further assessed the use of immunomodulators (azathio-
prine, methotrexate, and 6-mercaptopurine). Azathioprine is
the most used drug in combination with corticosteroids in the
initial stages of disease (Supplementary Fig. 1, Supplemental
digital content 1, http://links.lww.com/EJGH/A306). Almost all
patients with CD (93.4%) received any immunomodulator in
the first 5 years after diagnosis without any change over the two
periods. Immunomodulators are more and earlier used in CD
than in UC; this observation is consistent over the study period.
Biologicals
A significant shift toward earlier use of biologicals could
clearly be shown in the period of 2010 and after for all
patients with IBD (P<0.001) (Fig. 3a and b): 1 year after
diagnosis, 13.7% of patients with CD received any bio-
logical in the period up to 2009 with a 2.5-fold increase in
the period of 2010 and later. This impressive raise could
still be observed 2 years after diagnosis. Interestingly, after
5 years, the administration rate of anti-tumor necrosis
factor-α (anti-TNF-α) seemed somewhat similar in both
groups for CD (up to 2009: 58.1% and 2010 and later:
67.1%), whereas in UC/IC, this rate still remained almost
doubled after 5 years (up to 2009: 19.5% and 2010 and
later: 42.7%) (Table 3). In summary, both patients with
CD and those with UC/IC received biologicals significantly
earlier when diagnosed in 2010 and later (P=0.007 for
CD and P=0.013 for UC/IC). A trend can especially be
seen in severe cases of CD (L3 localization) and UC
(pancolitis) (Fig. 4a–d). Infliximab was the most used anti-
TNF-α agent in our study population, followed by adalimu-
mab and certolizumab (Supplementary Fig. 2, Supplemental
digital content 1, http://links.lww.com/EJGH/A306).
Complication rate
More surgical interventions could be observed in patients
with CD than those with UC (Table 4 and Fig. 5).
Interestingly, there was no change of complication rate
over time when comparing patients of both groups, despite
the more intensive treatment strategies and the availability
of more efficient drugs over time.
Discussion
The treatment of IBD, regardless of in pediatric or in
adult patients, was and still is a big challenge for health
professionals in all countries. In the past years, newer
drugs were approved for the use in children and different
concepts were employed. The present study represents the
former and the actual treatment strategies of pediatric
IBD in the largest pediatric IBD cohort of Switzerland.
The main results of our study demonstrate a significant
earlier initiation of anti-TNF-α and a concomitant
steroid-sparing effect in pediatric patients with CD during
the past decade.
Corticosteroids remain one of the main actors in the
treatment of severe IBD. With the increased use of biologicals,
the hope rose to reduce the use of systemic steroids and with it
the well-known adverse effects. This goal was reached in
pediatric patients with CD but surprisingly there was no
significant difference in patients with UC. Because of the
observational nature of this study, a cause-and-effect rela-
tionship between steroid sparing and the decrease of usage of
corticosteroids should be made with caution. There might be
other factors like different treatments between CD and UC
influencing the usage of steroids in patients with CD. For
example, we did not assess the exclusive enteral nutrition as
Table 2. Patient data stratified by diagnosis and year
Patients with CD
Diagnosed
2009 or earlier
(n=92)
Diagnosed
2010 or later
(n=104)
All patients
with CD
(N=196)
P value
2009
vs.
2010
Height z-score at enrollment
Mean (SD) −0.74 (1.2) −0.48 (1.2) −0.60 (1.2) 0.128
Range −3.7 to 2.0 −4.9 to 2.4 −4.9 to 2.4
Weight z-score at enrollment
Mean (SD) −0.73 (1.0) −0.32 (1.2) −0.51 (1.1) 0.012
Range −3.5 to 1.5 −3.6 to 2.4 −3.6 to 2.4
BMI z-score at enrollment
Mean (SD) −0.41 (1.1) −0.36 (1.0) −0.39 (1.1) 0.742
Range −3.4 to 1.9 −3.7 to 2.0 −3.7 to 2.0 –
EIM
None 62 (67.4) 62 (59.6) 124 (63.3) 0.260
Yes 30 (32.6) 42 (40.4) 72 (36.7) 0.408
Arthritis 16 (17.4) 23 (22.1) 39 (19.9) 0.189
Uveitis 4 (4.4) 1 (1.0) 5 (2.6) 0.469
Pyoderma
gangrenosum
1 (1.1) 0 (0.0) 1 (0.5) 0.069
Erythema
nodosum
1 (1.1) 7 (6.7) 8 (4.1) 0.284
Oral ulcers 14 (15.2) 22 (21.2) 36 (18.4) 0.102
Ankylosing
spondylitis
3 (3.3) 0 (0.0) 3 (1.5) 1.000
PSC 0 (0.0) 1 (1.0) 1 (0.5) –
Patients with
UC/IC
Diagnosed
2009 or earlier
(n=76)
Diagnosed
2010 or later
(n=106)
All patients with
UC/IC
(N=182)
P value
2009
vs.
2010
Height z-score at enrollment
Mean (SD) −0.37 (1.2) 0.02 (1.07) −0.14 (1.2) 0.025
Range −6.5 to 2.2 −3.1 to 2.2 −6.5 to 2.2
Weight z-score at enrollment
Mean (SD) −0.47 (1.3) 0.00 (1.1) −0.20 (1.2) 0.008
Range −4.5 to 3.0 −2.9 to 2.3 −4.5 to 3.0
BMI z-score at enrollment
Mean (SD) −0.15 (1.0) 0.01 (1.0) −0.06 (1.0) 0.326
Range −3.1 to 2.2 −2.6 to 2.3 −3.1 to 2.3
EIM
None 59 (77.6) 84 (79.3) 143 (78.6) 0.794
Yes 17 (22.4) 22 (20.8) 39 (21.4) 0.914
Arthritis 9 (11.8) 12 (11.3) 21 (11.5) 0.173
Uveitis 2 (2.6) 0 (0.0) 2 (1.1) 1.000
Pyoderma
gangrenosum
1 (1.3) 1 (0.9) 2 (1.1) 0.236
Erythema
nodosum
1 (1.3) 0 (0.0) 1 (0.6) 0.931
Oral ulcers 6 (7.9) 8 (7.6) 14 (7.7) 0.418
Ankylosing
spondylitis
1 (1.3) 0 (0.0) 1 (0.6) 0.041
PSC 0 (0.0) 6 (5.7) 6 (3.3) –
CD, Crohn’s disease; EIM, extraintestinal manifestations; IBD, inflammatory bowel
disease; IQR, interquartile range; PSC, primary sclerosing cholangitis; UC,
ulcerative colitis.
1162 European Journal of Gastroenterology & Hepatology October 2018 •Volume 30 •Number 10
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
primary induction therapy for CD owing to the study design
even though it is one of the most important treatment stra-
tegies in newer pediatric IBD. Other studies showed that up to
80% of pediatric patients with UC are treated with steroids
[6,7] and 60–65% of pediatric patients with IBD received a
treatment with prednisolone in the first 3 months after diag-
nosis [8]. This may be explained by severe initial disease that
gives the indication of systemic corticosteroids to quickly
improve the situation [9,10].
5-ASA is the treatment of choice in mild to moderate
UC, but currently there are no clear recommendations for
the use of 5-ASA in patients with CD because of weak
evidence on clinical improvement [10]. Probably because
of several publications over time including guidelines
[11–13], an important decline in the prescription of ami-
nosalicylates in patients with CD was observed in
our study. However, a big gap between international
guidelines and clinical practice persists. This observation
could also be demonstrated in adult patients with CD
in Switzerland [14] and was explained by a perceived
previous treatment response, the hope to perform a
chemoprevention on colonic dysplasia, the patient’s
expectations and that 5-ASA are generally considered as
relatively safe.
Infliximab was the first anti-TNF-α licensed and
approved for pediatric use by the US Fod and Drug
Administration in 2006. This study clearly showed an
earlier use of biologicals for pediatric patients with CD or
UC than a decade ago. The same observation could be
made in comparable Polish and American studies [15,16].
This change to a more intensive therapy can be seen in
several studies [15,17,18] and aims to prevent growth
failure and malnutrition in children. Church et al. [19]
demonstrated a significant improvement in height z-score
2 years after initiation of infliximab in children with
luminal CD, particularly when therapy is initiated early
(within 18 months). However, the improvement of linear
growth could only be observed in children with Tanner
stage 1 and 2 with a loss of effect in more advanced Tanner
stages. The newest consensus guidelines recommend early
introduction of anti-TNF-α in patients with CD with high
disease activity and features indicating poor prognosis [10].
Table 3. Cumulative proportion of used treatment with associated 95% confidence interval
Patients with CD Patients with UC
2009 and before 2010 and later 2009 and before 2010 and later
Immunomodulators
1 year 82.2 (72.2–88.5) 86.5 (77.5–91.9) 49.1 (36.5–59.2) 48.3 (37.4–57.3)
2 years 89.5 (80.8–94.6) 89.5 (80.8–94.2) 65.1 (52.5–60.1) 61.3 (49.2–70.5)
5 years 93.4 (85.5–97.0) Not applicable 72.6 (60.1–81.2) 69.0 (55.2–78.6)
Biologicals
1 year 13.7 (6.3–20.5) 34.7 (24.7–43.3) 7.3 (1.2–13.0) 16.6 (8.6–24.0)
2 years 28.3 (18.2–37.1) 55.7 (44.1–64.9) 12.5 (4.6–19.7) 28.2 (17.2–37.8)
5 years 58.1 (44.9–68.1) 67.1 (53.0–76.9) 19.5 (9.5–28.4) 42.7 (26.7–55.2)
Steroids
1 year 82.4 (72.7–88.7) 68.4 (57.9–76.3) 66.4 (53.9–75.5) 66.5 (55.7–74.7)
2 years 82.4 (72.7–88.7) 76.8 (66.6–83.9) 79.7 (68.2–76.2) 74.8 (63.4–82.6)
5 years 93.0 (84.7–96.8) Not applicable 87.2 (76.2–93.1) Not applicable
CD, Crohn’s disease; UC, ulcerative colitis.
Fig. 1. (a, b) Overview of main treatment usage in CD and UC. 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; UC, ulcerative colitis.
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In pediatric patients with UC, infliximab is normally
used after initial treatment with 5-ASA and immunomo-
dulators with persistent active or steroid dependent disease
[9]. Corticosteroid-free inactive disease under biological
therapy was observed in 38 and 21% of patients at 12 and
24 months, respectively [20]. The ACT 1 and 2 study
carried out on adult patients with UC showed that 77% of
patients remained responsive after induction with inflix-
imab for at least 1 year [21].
The ‘top-down’ treatment implicating early adminis-
tration of a biological agent with or without concomitant
immunomodulatory therapy has shown better remission
rates at 1 year compared with pediatric patients with CD
with conventional ‘step-up’ therapy [22]. This strategy
seems to be superior in maintaining clinical remission as
the study of Lee et al. [22] showed during an observation
period of 3 years. Despite the impressive incline of the use
of anti-TNF-α and biological treatment, studies have
shown good long-term effects with little risk of malig-
nancies [23,24].
Despite the advances in medical therapy, surgery is still
required in 18–33% of patients within the first 5 years of
disease [25], an observation which was confirmed in our
study. Two recent studies could relate a lesser number of
disease complications like bowel strictures with early
immunomodulatory or anti-TNF-α treatment, defined by
beginning within a 2-year period from diagnosis of CD
[26,27]. These studies were conducted in adult patients but
are comparable with other study results in children [18].
With our study, we could not demonstrate a reduction of
surgery within the first 5 years after diagnosis. These
results are limited by the observational design of our study
and its relatively small number of patients with compli-
cations but correlate with results from Italy in pediatric UC
[28]. In fact, although 80% of steroid-refractory pediatric
patients with acute severe UC received and responded
initialy to infliximab, still up to 50% required elective
colectomy during follow-up. Therefore, the authors sug-
gested that infliximab did not alter the long-term surgery
rate of pediatric acute severe UC. Besides, it is postulated
that this missing effect on the surgery rate might be
because of a significant subclinical and clinical disease
progression before diagnosis and before efficient treatment
that could have altered the disease course [16].
Results from an ongoing international multicentre
randomized controlled trial comparing the principle of
Fig. 2. Proportion of 5-ASA usage in CD since disease diagnosis for 2009 and
earlier versus 2010 and later. 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease.
Fig. 3. (a, b) Proportion of the usage of any biological since disease diagnosis in CD and UC for 2009 and earlier versus 2010 and later. CD, Crohn’s disease;
IC, indeterminate colitis; UC, ulcerative colitis.
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‘step-down’ (by using biologicals during the first year after
diagnosis) with ‘step up’ (by beginning with exclusive
enteral nutrition and corticoid treatment) strategy are
expected and will be of interest [29]. Our study has several
strengths and some limitations as well. We present data on
a large and well-characterized cohort of pediatric patients
with IBD. One limitation is that the results may not be
generalizable to the entire pediatric IBD population in
Switzerland as the SIBDCS is not population based
Second, exclusive enteral nutrition as primary induction
therapy for CD has not been assessed because of the study
design. Finally, we only applied L4 classification for upper
gastrointestinal involvement without discrimination of L4a
and L4b owing to the fact that the Paris classification was
published after the onset of our study.
Fig. 4. (a–d) Proportion of biological usage in CD and UC since disease diagnosis for 2009 and earlier versus 2010 and later. CD, Crohn’s disease;
UC, ulcerative colitis.
Table 4. Surgical interventions in detail for each disease
Operations CD UC/IC
Ileal resection 4 1
Ileo-cecal resection 7 0
Right colectomy 2 0
Left colectomy 2 0
Sigmoid resection 3 0
Other small bowel resection 1 0
Ileostomy 8 1
Colostomy 0 1
Perianal abscess drainage 20 1
Fistulectomy/fistulotomy 11 1
Seton drainage 3 0
Intra-abdominal abscess drainage 3 0
Subtotal colectomy 2 2
Total proctocolectomy 0 4
Total number 66 11
CD, Crohn’s disease; IC, indeterminate colitis; UC, ulcerative colitis.
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Conclusion
A significant earlier use of anti-TNF-α agents in pediatric
patients with IBD was observed in the past decade with
steroid-sparing effect in pediatric patients with CD.
Despite this change, no reduction of surgery rate has
occurred in Swiss pediatric patients with IBD.
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